- Home
- GNFT vs TVGN Comparison
GNFT vs TVGN Comparison
Compare GNFT & TVGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNFT
- TVGN
- Stock Information
- Founded
- GNFT 1999
- TVGN 2020
- Country
- GNFT France
- TVGN United States
- Employees
- GNFT N/A
- TVGN N/A
- Industry
- GNFT Biotechnology: Biological Products (No Diagnostic Substances)
- TVGN Blank Checks
- Sector
- GNFT Health Care
- TVGN Finance
- Exchange
- GNFT Nasdaq
- TVGN Nasdaq
- Market Cap
- GNFT 179.7M
- TVGN 174.4M
- IPO Year
- GNFT 2019
- TVGN N/A
- Fundamental
- Price
- GNFT $3.74
- TVGN $1.43
- Analyst Decision
- GNFT Strong Buy
- TVGN
- Analyst Count
- GNFT 1
- TVGN 0
- Target Price
- GNFT $13.00
- TVGN N/A
- AVG Volume (30 Days)
- GNFT 9.9K
- TVGN 4.9M
- Earning Date
- GNFT 09-19-2024
- TVGN 02-20-2025
- Dividend Yield
- GNFT N/A
- TVGN N/A
- EPS Growth
- GNFT N/A
- TVGN N/A
- EPS
- GNFT 0.47
- TVGN N/A
- Revenue
- GNFT $86,225,222.00
- TVGN N/A
- Revenue This Year
- GNFT $145.20
- TVGN N/A
- Revenue Next Year
- GNFT N/A
- TVGN N/A
- P/E Ratio
- GNFT $7.89
- TVGN N/A
- Revenue Growth
- GNFT 175.45
- TVGN N/A
- 52 Week Low
- GNFT $3.35
- TVGN $0.26
- 52 Week High
- GNFT $6.42
- TVGN $21.09
- Technical
- Relative Strength Index (RSI)
- GNFT 49.41
- TVGN 54.34
- Support Level
- GNFT $3.68
- TVGN $1.30
- Resistance Level
- GNFT $4.03
- TVGN $1.54
- Average True Range (ATR)
- GNFT 0.15
- TVGN 0.17
- MACD
- GNFT 0.05
- TVGN 0.01
- Stochastic Oscillator
- GNFT 57.35
- TVGN 35.14
About GNFT GENFIT S.A.
Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. It has one segment the research and development of innovative medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.
About TVGN Tevogen Bio Holdings Inc. Common Stock
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes ("CD8+ CTLs" or "CTLs"), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.